New drug cocktail aims to shrink lung tumors before surgery

NCT ID NCT07269782

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase II trial tests two drugs—HLX43 and serplulimab—given before surgery to people with stage II-IIIB non-small cell lung cancer. The goal is to see if the combination can reduce tumor size, making surgery more effective. About 60 participants will be enrolled to evaluate safety and how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX43 (an antibody-drug conjugate targeting PD-L1) combined with serplulimab (an anti-PD-1 antibody)
What this could lead to: If successful, this combination could shrink lung tumors before surgery, potentially improving surgical outcomes and long-term control of the disease.
What could go wrong: This is an early-phase trial with only 60 participants, so results may not apply to all patients. The combination may cause side effects or fail to improve outcomes compared to standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Pulmonary Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.